Lead Product(s) : Norethisterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Receives FDA Approval for Emzahh (Norethindrone Tablets USP), 0.35mg
Details : Norethisterone acts similarly to endogenous progesterone with a much higher potency, it acts at the pelvic level to alter cervical and endometrial function, as well as via the inhibition of pituitary hormones that play a role in follicular maturation and...
Product Name : Emzahh-Generic
Product Type : Hormone
Upfront Cash : Inapplicable
January 10, 2023
Lead Product(s) : Norethisterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Norethisterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Organon
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Prolonged Uterine Bleeding of Etonogestrel (ENG)-Releasing Implant
Details : Norethisterone is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Metrorrhagia.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
August 07, 2019
Lead Product(s) : Norethisterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Organon
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Norethisterone
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions
Details : Norethindrone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 29, 2011
Lead Product(s) : Norethisterone
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Norethisterone
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions
Details : Norethindrone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 22, 2011
Lead Product(s) : Norethisterone
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
